Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

The FDA has approved a live, oral, vaccine for the prevention of rotavirus gastroenteritis in infants. An earlier vaccine approved for this indication (RotaShield®) was withdrawn in 1999 due to an increased risk of intussusception. In a large trial, of more than 70,000 children, risk of intussusception was not observed with the new vaccine. The new oral rotavirus vaccine will be marketed by Merck & Co., Inc. as Rota Teq®.

Pharmacology Update: Rotavirus Vaccine, Live, Oral, Pentavalent (Rota Teq®)